Core Viewpoint - Hillenbrand reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, but down from $0.85 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +2.00%, with the company previously expected to post earnings of $0.54 per share but actually delivering $0.60, resulting in a surprise of +11.11% [2] - Hillenbrand's revenues for the quarter ended June 2025 were $598.9 million, surpassing the Zacks Consensus Estimate by 4.63%, compared to $786.6 million in revenues a year ago [3] - The company has consistently exceeded consensus revenue estimates over the last four quarters [3] Stock Performance - Hillenbrand shares have declined approximately 35.9% since the beginning of the year, while the S&P 500 has gained 8.6% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $558.9 million, and for the current fiscal year, it is $2.20 on revenues of $2.55 billion [8] - The outlook for the industry can significantly impact the stock's performance, with the Industrial Services sector currently ranking in the top 29% of over 250 Zacks industries [9]

Group 1 - Lincoln Educational Services Corporation (LINC) reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and showing an increase from $0.06 per share a year ago, representing an earnings surprise of +125.00% [1] - The company posted revenues of $116.47 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.99%, and an increase from $102.91 million year-over-year [2] - Lincoln Educational Services has outperformed the S&P 500, with shares increasing about 50.1% since the beginning of the year compared to the S&P 500's gain of 8.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $129.27 million, and for the current fiscal year, it is $0.72 on revenues of $490.47 million [7] - The Zacks Industry Rank indicates that the Schools industry is currently in the top 12% of over 250 Zacks industries, suggesting a favorable outlook for companies within this sector [8]

Company Performance - LivePerson reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.20, and a significant improvement from a loss of $0.69 per share a year ago, resulting in an earnings surprise of +45.00% [1] - The company posted revenues of $59.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.19%, although this represents a decline from year-ago revenues of $79.88 million [2] - Over the last four quarters, LivePerson has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - LivePerson shares have declined approximately 20.4% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $57.56 million, and for the current fiscal year, it is -$0.63 on revenues of $240.99 million [7] Industry Outlook - The Internet - Services industry, to which LivePerson belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LivePerson's stock performance [5]

Myomo, Inc. (MYO) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. Ahead of this earnings release, the estimate revisions trend for Myomo was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares ...

Financial Performance - EuroDry reported a quarterly loss of $1.1 per share, which was better than the Zacks Consensus Estimate of a loss of $1.23, but worse than a loss of $0.17 per share a year ago, indicating a significant decline [1] - The company posted revenues of $11.28 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.09% and down from $17.44 million year-over-year [2] - Over the last four quarters, EuroDry has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - EuroDry shares have declined approximately 9.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for EuroDry is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.90 on revenues of $12.89 million, and for the current fiscal year, it is -$5.12 on revenues of $46.03 million [7] - The trend of estimate revisions for EuroDry was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Transportation - Shipping industry, to which EuroDry belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.98 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.63 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 98.58%, while revenues were zero a year ago [2] - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.93 on revenues of $1.06 million, and for the current fiscal year, it is -$3.45 on revenues of $4.17 million [7] - The estimate revisions trend for 4D Molecular Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Viewpoint - Payoneer Global Inc. (PAYO) has seen a 2.5% increase in share price over the past four weeks, closing at $6.64, with analysts suggesting a potential upside of 44% based on a mean price target of $9.56 [1][11]. Price Targets and Analyst Estimates - The mean estimate for PAYO comprises nine short-term price targets with a standard deviation of $1.67, indicating variability among analysts [2]. - The lowest price target is $7.00, suggesting a 5.4% increase, while the highest target is $12.00, indicating an 80.7% potential increase [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with two estimates moving higher and no negative revisions [12]. - PAYO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to historical inaccuracies in predicting stock movements [3][7]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8][10].

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. While Humacyte, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnin ...

Monday.com (MNDY) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +29.76%. A quarter ago, it was expected that this project management software developer would post earnings of $0.7 per share when it actually produced earnings of $1.1, delivering a surprise of +57.14%.Over the last fo ...

Core Viewpoint - Green Plains Renewable Energy (GPRE) reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.28, and compared to a loss of $0.38 per share a year ago [1][2]. Financial Performance - The company experienced an earnings surprise of -46.43% for the quarter, having previously expected a loss of $0.51 per share but reporting a loss of $0.88, resulting in a surprise of -72.55% [2]. - Green Plains posted revenues of $552.83 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 6.66%, and down from $618.83 million in the same quarter last year [3]. - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has topped consensus revenue estimates just once [2][3]. Stock Performance - Green Plains shares have declined approximately 21.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [4]. - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [7]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $599.3 million, and for the current fiscal year, it is -$1.33 on revenues of $2.4 billion [8]. - The estimate revisions trend for Green Plains was mixed ahead of the earnings release, and future revisions may change following the recent report [7]. Industry Context - The Chemical - Specialty industry, to which Green Plains belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [9].